181 related articles for article (PubMed ID: 18459457)
1. Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer.
Musiał J; Sporny S; Nowicki A
Pol J Pathol; 2007; 58(4):235-43. PubMed ID: 18459457
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
3. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.
Umbas R; Isaacs WB; Bringuier PP; Schaafsma HE; Karthaus HF; Oosterhof GO; Debruyne FM; Schalken JA
Cancer Res; 1994 Jul; 54(14):3929-33. PubMed ID: 7518346
[TBL] [Abstract][Full Text] [Related]
4. N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin.
Song Y; Oda Y; Hori M; Kuroiwa K; Ono M; Hosoi F; Basaki Y; Tokunaga S; Kuwano M; Naito S; Tsuneyoshi M
Hum Pathol; 2010 Feb; 41(2):214-22. PubMed ID: 19800102
[TBL] [Abstract][Full Text] [Related]
5. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival.
Richmond PJ; Karayiannakis AJ; Nagafuchi A; Kaisary AV; Pignatelli M
Cancer Res; 1997 Aug; 57(15):3189-93. PubMed ID: 9242448
[TBL] [Abstract][Full Text] [Related]
6. Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer.
Elzagheid A; Korkeila E; Bendardaf R; Buhmeida A; Heikkilä S; Vaheri A; Syrjänen K; Pyrhönen S; Carpén O
Hum Pathol; 2008 Dec; 39(12):1737-43. PubMed ID: 18701134
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes.
Ray ME; Mehra R; Sandler HM; Daignault S; Shah RB
J Urol; 2006 Oct; 176(4 Pt 1):1409-14; discussion 1414. PubMed ID: 16952645
[TBL] [Abstract][Full Text] [Related]
8. Cadherin switching in human prostate cancer progression.
Tomita K; van Bokhoven A; van Leenders GJ; Ruijter ET; Jansen CF; Bussemakers MJ; Schalken JA
Cancer Res; 2000 Jul; 60(13):3650-4. PubMed ID: 10910081
[TBL] [Abstract][Full Text] [Related]
9. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.
Umbas R; Schalken JA; Aalders TW; Carter BS; Karthaus HF; Schaafsma HE; Debruyne FM; Isaacs WB
Cancer Res; 1992 Sep; 52(18):5104-9. PubMed ID: 1516067
[TBL] [Abstract][Full Text] [Related]
10. Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer.
Aaltomaa S; Lipponen P; Ala-Opas M; Eskelinen M; Kosma VM
Br J Cancer; 1999 May; 80(3-4):477-82. PubMed ID: 10408856
[TBL] [Abstract][Full Text] [Related]
11. Adhesion molecules as prognostic markers in pancreatic adenocarcinoma.
Torer N; Kayaselcuk F; Nursal TZ; Yildirim S; Tarim A; Nòyan T; Karakayali H
J Surg Oncol; 2007 Oct; 96(5):419-23. PubMed ID: 17874463
[TBL] [Abstract][Full Text] [Related]
12. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
13. Aerodigestive tract invasion by well-differentiated thyroid carcinoma: diagnosis, management, prognosis, and biology.
McCaffrey JC
Laryngoscope; 2006 Jan; 116(1):1-11. PubMed ID: 16481800
[TBL] [Abstract][Full Text] [Related]
14. [Expressions of E-cadherin in non-small cell lung cancer and it correlation with prognosis].
Qiao GB; Wu YL; Ou W; Yang XN; Zhong WZ; Lin JY; Zhao J; Xie D; Guan XY
Zhonghua Wai Ke Za Zhi; 2005 Jul; 43(14):913-7. PubMed ID: 16083620
[TBL] [Abstract][Full Text] [Related]
15. Ezrin expression in prostate cancer and benign prostatic tissue.
Valdman A; Fang X; Pang ST; Nilsson B; Ekman P; Egevad L
Eur Urol; 2005 Nov; 48(5):852-7. PubMed ID: 16230228
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of dysadherin expression in patients with non-small cell lung cancer.
Tamura M; Ohta Y; Tsunezuka Y; Matsumoto I; Kawakami K; Oda M; Watanabe G
J Thorac Cardiovasc Surg; 2005 Sep; 130(3):740-5. PubMed ID: 16153922
[TBL] [Abstract][Full Text] [Related]
17. The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients' survival.
Lazăr D; Tăban S; Ardeleanu C; Dema A; Sporea I; Cornianu M; Lazăr E; Vernic C
Rom J Morphol Embryol; 2008; 49(4):459-67. PubMed ID: 19050793
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of E-cadherin in the progression of rat prostatic cancer.
Bussemakers MJ; van Moorselaar RJ; Giroldi LA; Ichikawa T; Isaacs JT; Takeichi M; Debruyne FM; Schalken JA
Cancer Res; 1992 May; 52(10):2916-22. PubMed ID: 1581909
[TBL] [Abstract][Full Text] [Related]
19. Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome.
Pyo SW; Hashimoto M; Kim YS; Kim CH; Lee SH; Johnson KR; Wheelock MJ; Park JU
J Craniomaxillofac Surg; 2007 Jan; 35(1):1-9. PubMed ID: 17296306
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of combined expression of MUC1 and adhesion molecules in advanced gastric cancer.
Ohno T; Aihara R; Kamiyama Y; Mochiki E; Asao T; Kuwano H
Eur J Cancer; 2006 Jan; 42(2):256-63. PubMed ID: 16356709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
